Oragenics Inc. has submitted the required regulatory and ethics approvals to proceed with its Phase 2 clinical trial of ONP-002, a novel intranasal neurosteroid for concussion and mild traumatic brain injury, in Australia. The company's planned site activation is affected by an ongoing health-system consolidation in Victoria, which has delayed final verification of Human Research Ethics Committee (HREC) approval and extended the timeline for clinical site onboarding and patient dosing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oragenics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9648442-en) on February 09, 2026, and is solely responsible for the information contained therein.